Halozyme <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports 41% Increase in Total Revenue and 77% Rise in Net Income for <a href="https://laohu8.com/S/QTWO">Q2</a> 2025; Raises 2025 Financial Guidance
Halozyme Therapeutics Inc. reported robust financial results for the second quarter of 2025, with total revenue increasing by 41% year-over-year to $326 million and royalty revenue surging by 65% year-over-year to $206 million. The company's net income rose by 77% year-over-year to reach $165 million. Additionally, the GAAP Diluted EPS saw an 85% increase year-over-year to $1.33, while Non-GAAP Diluted EPS increased by 69% year-over-year to $1.54. The company also raised its full-year 2025 financial guidance, projecting total revenue to be in the range of $1,275 to $1,355 million, reflecting a year-over-year growth of 26% to 33%. Adjusted EBITDA guidance was also increased to a range of $865 to $915 million, indicating a growth of 37% to 45% year-over-year. Non-GAAP Diluted EPS is now anticipated to be between $6.00 and $6.40, representing a growth of 42% to 51% year-over-year. Significant business updates include the authorization of a third $250 million share repurchase tranche under a $750 million authorized plan. The company achieved notable regulatory milestones with approvals in Europe and the US, including the RYBREVANT SC and VYVGART Hytrulo products. Halozyme continues to expand its ENHANZE drug delivery technology, enhancing its growth trajectory and patient access globally.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA44813) on August 05, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.